These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 16119973

  • 1. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D, Heeley E, Hughes K, Shakir SA.
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D, Hughes K, Harris S, Shakir SA.
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D, Hughes K, Harris S, Shakir SA.
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D, Heeley E, Hughes K, Shakir SA.
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [Abstract] [Full Text] [Related]

  • 6. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D, Wilton LV, Shakir SA.
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [Abstract] [Full Text] [Related]

  • 7. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
    Harrison-Woolrych M, Herbison P, McLean R, Ashton J, Slattery J.
    Drug Saf; 2005 Sep; 28(5):435-42. PubMed ID: 15853444
    [Abstract] [Full Text] [Related]

  • 8. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
    Lee YH, Ji JD, Song GG.
    Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
    [Abstract] [Full Text] [Related]

  • 9. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 10. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA.
    Drug Saf; 2006 Jul; 29(8):687-96. PubMed ID: 16872242
    [Abstract] [Full Text] [Related]

  • 11. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY, Tsai YW, Huang WF.
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [Abstract] [Full Text] [Related]

  • 12. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Nov; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 13. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Nov; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 14. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.
    Ann Intern Med; 2005 Feb 01; 142(3):157-64. PubMed ID: 15684203
    [Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG.
    J Rheumatol; 2005 Jan 01; 32(1):111-7. PubMed ID: 15630735
    [Abstract] [Full Text] [Related]

  • 16. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
    Gudbjornsson B, Thorsteinsson SB, Sigvaldason H, Einarsdottir R, Johannsson M, Zoega H, Halldorsson M, Thorgeirsson G.
    Eur J Clin Pharmacol; 2010 Jun 01; 66(6):619-25. PubMed ID: 20157701
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT.
    Drug Saf; 2006 Jun 01; 29(3):261-72. PubMed ID: 16524325
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 01; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 19. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 01; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 20. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
    Lévesque LE, Brophy JM, Zhang B.
    CMAJ; 2006 May 23; 174(11):1563-9. PubMed ID: 16670396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.